172 related articles for article (PubMed ID: 17051594)
1. In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver.
Katoh M; Sawada T; Soeno Y; Nakajima M; Tateno C; Yoshizato K; Yokoi T
J Pharm Sci; 2007 Feb; 96(2):428-37. PubMed ID: 17051594
[TBL] [Abstract][Full Text] [Related]
2. Chimeric mice with humanized liver.
Katoh M; Tateno C; Yoshizato K; Yokoi T
Toxicology; 2008 Apr; 246(1):9-17. PubMed ID: 18248870
[TBL] [Abstract][Full Text] [Related]
3. Application of chimeric mice with humanized liver for predictive ADME.
Katoh M; Yokoi T
Drug Metab Rev; 2007; 39(1):145-57. PubMed ID: 17364883
[TBL] [Abstract][Full Text] [Related]
4. Expression of human cytochromes P450 in chimeric mice with humanized liver.
Katoh M; Matsui T; Nakajima M; Tateno C; Kataoka M; Soeno Y; Horie T; Iwasaki K; Yoshizato K; Yokoi T
Drug Metab Dispos; 2004 Dec; 32(12):1402-10. PubMed ID: 15383493
[TBL] [Abstract][Full Text] [Related]
5. Current status of prediction of drug disposition and toxicity in humans using chimeric mice with humanized liver.
Kitamura S; Sugihara K
Xenobiotica; 2014 Jan; 44(2):123-34. PubMed ID: 24329499
[TBL] [Abstract][Full Text] [Related]
6. Propagation of Human Hepatocytes in uPA/SCID Mice: Producing Chimeric Mice with Humanized Liver.
Ohshita H; Tateno C
Methods Mol Biol; 2017; 1506():91-100. PubMed ID: 27830547
[TBL] [Abstract][Full Text] [Related]
7. Near completely humanized liver in mice shows human-type metabolic responses to drugs.
Tateno C; Yoshizane Y; Saito N; Kataoka M; Utoh R; Yamasaki C; Tachibana A; Soeno Y; Asahina K; Hino H; Asahara T; Yokoi T; Furukawa T; Yoshizato K
Am J Pathol; 2004 Sep; 165(3):901-12. PubMed ID: 15331414
[TBL] [Abstract][Full Text] [Related]
8. Humanization of excretory pathway in chimeric mice with humanized liver.
Okumura H; Katoh M; Sawada T; Nakajima M; Soeno Y; Yabuuchi H; Ikeda T; Tateno C; Yoshizato K; Yokoi T
Toxicol Sci; 2007 Jun; 97(2):533-8. PubMed ID: 17341479
[TBL] [Abstract][Full Text] [Related]
9. Development of Murine Cyp3a Knockout Chimeric Mice with Humanized Liver.
Kato K; Ohbuchi M; Hamamura S; Ohshita H; Kazuki Y; Oshimura M; Sato K; Nakada N; Kawamura A; Usui T; Kamimura H; Tateno C
Drug Metab Dispos; 2015 Aug; 43(8):1208-17. PubMed ID: 25979261
[TBL] [Abstract][Full Text] [Related]
10. In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver.
Katoh M; Matsui T; Nakajima M; Tateno C; Soeno Y; Horie T; Iwasaki K; Yoshizato K; Yokoi T
Drug Metab Dispos; 2005 Jun; 33(6):754-63. PubMed ID: 15769886
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo.
Henderson CJ; McLaughlin LA; Scheer N; Stanley LA; Wolf CR
Mol Pharmacol; 2015 Apr; 87(4):733-9. PubMed ID: 25657337
[TBL] [Abstract][Full Text] [Related]
12. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.
Bertelsen KM; Venkatakrishnan K; Von Moltke LL; Obach RS; Greenblatt DJ
Drug Metab Dispos; 2003 Mar; 31(3):289-93. PubMed ID: 12584155
[TBL] [Abstract][Full Text] [Related]
13. 4-Hydroxylation of debrisoquine by human CYP1A1 and its inhibition by quinidine and quinine.
Granvil CP; Krausz KW; Gelboin HV; Idle JR; Gonzalez FJ
J Pharmacol Exp Ther; 2002 Jun; 301(3):1025-32. PubMed ID: 12023534
[TBL] [Abstract][Full Text] [Related]
14. Generation of Novel Chimeric Mice with Humanized Livers by Using Hemizygous cDNA-uPA/SCID Mice.
Tateno C; Kawase Y; Tobita Y; Hamamura S; Ohshita H; Yokomichi H; Sanada H; Kakuni M; Shiota A; Kojima Y; Ishida Y; Shitara H; Wada NA; Tateishi H; Sudoh M; Nagatsuka S; Jishage K; Kohara M
PLoS One; 2015; 10(11):e0142145. PubMed ID: 26536627
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of debrisoquin clearance in perfused rat livers and inhibition of dextromethorphan metabolism in human liver microsomes by 4-hydroxydebrisoquin or other metabolites of debrisoquin.
Jaruratanasirikul S; Cooper AD; Blaschke TF
Drug Metab Dispos; 1992; 20(3):379-82. PubMed ID: 1355711
[TBL] [Abstract][Full Text] [Related]
16. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.
Vanwolleghem T; Meuleman P; Libbrecht L; Roskams T; De Vos R; Leroux-Roels G
Gastroenterology; 2007 Oct; 133(4):1144-55. PubMed ID: 17919490
[TBL] [Abstract][Full Text] [Related]
17. Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver.
Sanoh S; Horiguchi A; Sugihara K; Kotake Y; Tayama Y; Ohshita H; Tateno C; Horie T; Kitamura S; Ohta S
Drug Metab Dispos; 2012 Feb; 40(2):322-8. PubMed ID: 22048522
[TBL] [Abstract][Full Text] [Related]
18. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera.
Meuleman P; Libbrecht L; De Vos R; de Hemptinne B; Gevaert K; Vandekerckhove J; Roskams T; Leroux-Roels G
Hepatology; 2005 Apr; 41(4):847-56. PubMed ID: 15791625
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
20. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse.
Corchero J; Granvil CP; Akiyama TE; Hayhurst GP; Pimprale S; Feigenbaum L; Idle JR; Gonzalez FJ
Mol Pharmacol; 2001 Dec; 60(6):1260-7. PubMed ID: 11723233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
